Mufg Securities Americas Inc. Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Mufg Securities Americas Inc. acquired a new position in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,706 shares of the medical research company’s stock, valued at approximately $645,000.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Malaga Cove Capital LLC raised its position in shares of Edwards Lifesciences by 3.4% during the 4th quarter. Malaga Cove Capital LLC now owns 10,176 shares of the medical research company’s stock valued at $753,000 after buying an additional 339 shares in the last quarter. Man Group plc increased its position in shares of Edwards Lifesciences by 26.3% during the 4th quarter. Man Group plc now owns 559,450 shares of the medical research company’s stock valued at $41,416,000 after purchasing an additional 116,528 shares during the last quarter. NorthRock Partners LLC raised its holdings in shares of Edwards Lifesciences by 102.7% during the 4th quarter. NorthRock Partners LLC now owns 20,097 shares of the medical research company’s stock valued at $1,488,000 after buying an additional 10,183 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Edwards Lifesciences by 39.4% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 9,760 shares of the medical research company’s stock worth $723,000 after buying an additional 2,760 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp lifted its position in Edwards Lifesciences by 2.7% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 133,400 shares of the medical research company’s stock worth $9,876,000 after buying an additional 3,481 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This trade represents a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,098 shares of the company’s stock, valued at approximately $3,057,691.20. This trade represents a 21.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,931 shares of company stock valued at $5,148,028 in the last quarter. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

EW has been the topic of several research reports. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, April 25th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Piper Sandler raised their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Robert W. Baird upped their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $79.60.

Edwards Lifesciences Price Performance

Shares of EW opened at $77.04 on Thursday. The firm’s 50-day simple moving average is $71.73 and its two-hundred day simple moving average is $71.62. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The stock has a market cap of $45.19 billion, a PE ratio of 11.05, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the company earned $0.66 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.